hahahah! You are that far behind sunshine.
the type D meeting was to review the adrenal function monitoring in the dosing (stage 1) arm of phase 3 and the pre clinical trial work completed on this subject matter only, that was agreed to be completed due to the vacuole that formed in 1 rodent back in 2020 when the company was applying for the 5052b pathway to market. The vacuole is a relatively rare but well known furphy in rodent physiology in lab trials, not attributed to the drug molecule.
Paul has addressed the his too many times to give you a reference. Pick any Q and A section in any recent webinar and it’s bound to come up.
hahahah! You are that far behind sunshine. the type D meeting...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.005(2.08%) |
Mkt cap ! $85.73M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 25.0¢ | 23.0¢ | $180.4K | 746.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 79748 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 22818 | 4 |
View Market Depth
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |